All In Biotech

Drug Trial Radar · NCT04644185

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

A Multicenter, Adaptive, Randomized, Double-blinded, Placebo-controlled Phase II/III Trial to Evaluate the Efficacy and Safety of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Hospitalized Patients With Severe COVID-19

Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

102

Actual

Start

Mar 27, 2021

Primary completion

Dec 29, 2021

Study completion Feb 11, 2022

Sponsor

Lead sponsor
Sinocelltech Ltd.Industry
Sponsor type
Industry
First posted
Nov 25, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally. The study is comprised of two parts: dose selection (Phase II) and pivotal treatment effect (Phase III).

Conditions

  • Covid19

Interventions

  • SCTA01Drug

    SCTA01, a recombinant anti-SARS-CoV-2 spike protein monoclonal antibody

  • PlaceboOther

    all SCTA01 excipients without active component+best supportive care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Clinical Improvement up to Day 29Time frame: Day 29

Locations

7 sites in 7 countries. Site status is shown where the registry gives one.

  • SCT study site

    Somers Point, New Jersey

  • SCT study site

    Buenos Aires, Argentina

  • SCT study site

    Uberlândia, Brazil

  • SCT study site

    Talca, Chile

  • SCT study site

    Rionegro, Colombia

  • SCT study site

    Monterrey, Mexico

  • SCT study site

    Lima, Peru

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.